Soluble fibroblast growth factor receptor 3 (FGR3) polypeptide for use in the prevention or treatment of skeletal growth retardation disorders
US10724014B2 · kind B2 · utility
4Cited by
21References
14Claims
0Family size
Assignees
Inventor
Key dates
| Filing date | Jan 16, 2014 |
| Grant date | Jul 28, 2020 |
| Priority date | — |
| Expiry date | Jan 16, 2034 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC12Y207/10001
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present invention relates to the prevention or treatment of skeletal growth retardation disorders, in particular skeletal diseases, developed by patients that display abnormal increased activation of the fibroblast growth factor receptor 3 (FG-FR3), in particular by expression of a prolonged activated mutant of FGFR3. More particularly, the present invention relates to a soluble FGFR3 for use in the prevention or treatment of achondroplasia.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.